Essential Thrombocythemia (ET) Clinical Trial
Official title:
A Phase 3, Open-label, Single-arm Study Evaluating the Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Who Are Intolerant or Refractory to Current Cytoreductive Treatment
The purpose of this study is to investigate how effective and safe SPD422 (Anagrelide Hydrochloride) is in Japanese subjects, diagnosed with Essential Thrombocythemia, who's previously treatment has either not been effective or has caused unacceptable adverse reactions. The study will aim to show that platelet counts can be safely reduced in treated patients to below 600 x 10^9/L after a minimum of three months treatment. To demonstrate an positive effect platelet levels will need to remain below 600 x 10^9/L for at least 4 weeks.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01198717 -
Pediatric Disease Registry in Essential Thrombocythaemia (ET)
|
||
| Completed |
NCT01467661 -
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
|
Phase 3 | |
| Active, not recruiting |
NCT02577926 -
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
|
Phase 2 | |
| Completed |
NCT03625895 -
Agrylin Drug Use-Result Survey
|
||
| Completed |
NCT01816256 -
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
|
N/A | |
| Completed |
NCT01352585 -
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
|
||
| Completed |
NCT04243122 -
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
|
Phase 2 |